Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Oxford is one of 28 sites that will benefit from over £160 million awarded over five years to expand early phase clinical research for the benefit of NHS patients.

Doctor with a patient

The National Institute for Health Research (NIHR) has announced funding for its Clinical Research Facilities (CRF). The NIHR Oxford Clinical Research Facility is one of five new facilities and will be hosted by Oxford University Hospitals (OUH) NHS Foundation Trust. The Oxford Health Clinical Research Facility was also awarded funding.

CRFs support the delivery of early translational and experimental medicine research, from studies testing new treatments in patients for the very first time (first-in-human trials) through to early safety and efficacy trials (Phase II trials). They provide dedicated purpose-built facilities and expertise for the delivery of high-intensity studies funded by the NIHR, charities, the life sciences industry and other organisations.

The Oxford Experimental Medicine Clinical Research Facility (EMCRF) based at the Churchill Hospital, will act as the hub of the Oxford CRF. It provides a resource for early phase, experimental research across the University of Oxford's Medical Sciences Division. The EMCRF is central to the clinical translational strategy of the Oxford Biomedical Research Centre (BRC), providing service to all specialities in the BRC Themes.

Professor Duncan Richards, Director of the NIHR Oxford CRF and the EMCRF, commented: "This is a welcome opportunity to become part of the NIHR CRF Network. It represents an important new resource to support clinical translation across the University's Medical Sciences Division.

"The new facilities and collaboration with other capabilities in Oxford enhances our ability to deliver a wider range of early phase studies for the benefit of patients. Training and developing a new generation of doctors, nurses and allied health professionals in early phase experimental medicine trials is also core to our mission and we welcome NIHR's support for this." 

Professor Helen McShane, Director of the NIHR Oxford BRC, said: "This announcement is very welcome, as it will allow Oxford to expand the early phase clinical trials we conduct – much of it with Oxford BRC funding – that can be translated into tangible life-changing benefits for NHS patients. We also see it as a great opportunity to develop the skills and experience of young researchers in carrying out early phase experimental medicine trials."

Read the full story on the Oxford NIHR Biomedical Research Centre website.

Similar stories

Professor Michael Dustin appointed new Chair in Molecular Immunology

A generous gift from the Kennedy Trust for Rheumatology Research has enabled the creation of a new Chair in Molecular Immunology at the University of Oxford.

Empowering data science for single-cell analysis in Zimbabwe

An innovative computational biology training module was launched in November 2022 at the African Institute of Biomedical Science and Technology (AiBST) in Harare, Zimbabwe, where MSc students were trained in single-cell RNA sequencing data analysis.

T-cell coreceptors are well endowed—with kinases!

The kinase occupancy of CD4 and CD8 coreceptors is high, according to a new study published in PNAS.

Two prestigious Hunterian Professorships awarded to NDORMS researchers

Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Patients like me

What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.